← Human Trials & Peer-Reviewed Studies
Effect of anthelmintic treatment on serum free IGF-1 and IGFBP-3: a cluster-randomized-controlled trial in Indonesia
Plain-language guide to PMID 33149205 (2020): placebo-controlled randomized controlled trial study of IGF-1 LR3 in 3, adults.
Key Facts
- PMID
- 33149205
- Journal
- Scientific reports
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Kurniawan F et al. (10 authors)
- DOI
- 10.1038/s41598-020-75781-4
What This Study Did, in Plain Language
What Was Tested
Researchers studied IGF-1 LR3 in this randomized controlled trial publication.
In children, soil-transmitted helminth infections have been linked to poor nutritional status and growth retardation in association with lower levels of IGF-1.
In adults, IGF-1 has an anabolic and metabolic function and is related to nutritional status.
Who Took Part
The study group was 3, adults.
The age groups tagged for this paper are young children, children and adults, both men and women.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
Because people in this IGF-1 LR3 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
A placebo (an inactive look-alike) gave the IGF-1 LR3 group a baseline to be compared against.
Helminth infection status was assessed by microscopy (Kato-Katz) and PCR.
What Was Measured
In children, soil-transmitted helminth infections have been linked to poor nutritional status and growth retardation in association with lower levels of IGF-1.
Here, the researchers assessed the impact of helminth infection on free IGF-1 and its major binding protein, IGFBP-3, in adults.
The subject headings attached to it are Albendazole, Anthelmintics, Case-Control Studies, Cluster Analysis, Helminthiasis, Indonesia and Insulin-Like Growth Factor Binding Protein 3.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of IGF-1 LR3 in 3, adults.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2020 (Scientific reports), a journal based in England.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.